Company: INMB
Filing Date: 2025-03-07
Form Type: 424B5
Source: 0001213900-25-021719
Chunk: 36

Company: Inmune Bio, Inc.
Filing Date: 2025-03-07
Form: 424B5
Chunk 36
---
 we continue our research and development of, and seek regulatory
approvals for, our product candidates. The size of our future net losses will depend, in part, on the rate of future growth of our expenses
and our ability to generate revenues, if any.

Our recurring net losses and
negative cash flows from operations raised substantial doubt regarding our ability to continue as a going concern within one year after
the issuance of our consolidated financial statements for the year ended December 31, 2023. Until we can generate sufficient revenue from
the commercialization of our product candidates, we expect to finance our operations through the public or private sale of equity, debt
financings or other capital sources, such as government funding, collaborations, strategic alliances, divestment of non-core assets, or
licensing arrangements with third parties. To date, the Company has relied on equity and debt financing to fund its operations.

<div align='center'>3</div>

Implications of Being an Emerging Growth Company and a Smaller Reporting Company

We qualify as an “emerging growth company”
as defined in Section 2(a)(19) of the Securities Act of 1933, as modified by the Jumpstart Our Business Startups Act of 2012, or
the “JOBS Act.” As such, we take advantage of certain exemptions from various reporting requirements applicable to other public
companies that are not emerging growth companies for as long as we continue to be an emerging growth company, including (i) the exemption
from the auditor attestation requirements with respect to internal control over financial reporting under Section 404 of the Sarbanes-Oxley
Act of 2002 (the “Sarbanes-Oxley Act”), (ii) the exemptions from say-on-pay, say-on-frequency and say-on-golden parachute
voting requirements and (iii) reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements.
As a result, our stockholders may not have access to certain information they deem important. We will remain an emerging growth company
until the earliest of (i) the last day of the fiscal year (a) December 31, 2024, which is the last day of the fiscal year following the
fifth anniversary of the date of the first sale of the Company’s common stock, (b) in which we have total annual gross revenue of
at least $1.235 billion or (c) in which INmune Bio is deemed to be a large accelerated filer